Team

Co-Founder, CEO

Sara has a doctoral degree in Immunology from Gothenburg University and has been managing the Sortilin-project from research into product development. She has extensive experience in cancer research and has been the lead scientists for the Sortilin-project initiated at the Gothenburg University. She co-founded Sortina Pharma together with professor Göran Landberg and GU Ventures in 2020.

Co-Founder, CSO

Göran Landberg is a professor and senior consultant in pathology and the principal investigator of a research group at the Sahlgrenska Center for Cancer Research at University of Gothenburg. His research interest is focused on molecular pathology based translational projects with a goal to develop novel diagnostic and treatment principles for cancer patients, better targeting true malignant features.

CFO

Lena, a business economist, graduated from the School of Business, Economics and Law at the University of Gothenburg. With over 15 years of experience as a CFO in two distinct manufacturing companies, and an additional 4 years as a finance manager in real estate. Since May 2023, Lena has served as a CFO consultant at GU Ventures, where she currently holds the position of CFO at Sortina Pharma.

Lead Medicinal Chemist

Christer has a PhD in chemistry from University of Lund, Vice President of Medicinal Chemistry at Antaros Medical, Sweden. Christer has extensive experience in Medicinal Chemistry and drug hunting from working 30 years at AstraZeneca in Mölndal, Sweden. This experience covers all stages of drug hunting, from hit identification, lead generation and to lead optimization phases.

Lead DMPK specialist

Anna-Lena has more than 30 years of pharmaceutical industry experience around Biopharmaceutics and DMPK; AstraZeneca R&D between 1987 to 2013 and UCB BioPharma SPRL from 2013 to 2020. Anna-Lena has more than 85 publications, both original articles and book chapters as well as numerous posters and oral communications.

Clinical Development

Peter has over 30 years of clinical-scientific experience, first in clinical practice and more than 15 years in global clinical development within the oncology therapeutic area in the pharmaceutical and biotech industry. Since 2007, he has been leading and contributing to the development of several oncology agents in progressively responsible global development positions.

Patent Attorney, Barker Brettell

Henrik has a wealth of experience advising clients in the fields of biotechnology, life sciences, medical devices and telecommunications, drafting and prosecuting patent applications, oppositions and appeals. He works with a broad range of clients, from start-ups through large international corporations, and has particular experience in the life sciences and medical sectors, working with universities and spin-out companies.

Pre-Clinical drug development

Tommy has a background in AstraZeneca cardiovascular drug discovery, where he was responsible for bringing candidate drugs to clinical development. He has also given strong preclinical scientific support to AstraZeneca marketed cardiovascular drugs such as metoprolol (beta-blocker), felodipin (Ca2+-blocker), ramipiril (ACE inhibitors) and candesartan (AngII receptor inhibitor).

Regulatory Affairs

Anna Koptina Gültekin is an experienced Regulatory Affairs professional and consultant for cell and gene therapies/ATMPs in immuno oncology. She has expertise in regulatory strategies, expedited programs, and interactions with FDA, EMA and other authorities. She is the Head of Regulatory Affairs at Mendus AB and a Senior Regulatory Advisor for several Biotech companies. She also has a background in Global Regulatory Affairs for Device-based and Biologic products at Galderma, and a PhD in Biotechnology with academic research experience in Sweden, Germany and the US.

Business Advisor - CEO Biosector -Japan

Stefan is a Swedish business professional based in Tokyo since 2007 with an educational background in Chemical Engineering and Medicine from Umeå University. An experienced CEO of multiple industrial companies specializing in commercialization, first sales, and business development. Accredited business consultant in Germany and an expert in Japan-EU business relations.

Computational Chemist

Thomas is an Assistant Professor at Chalmers University and with over 15 years in the early discovery of new drugs at AstraZeneca. Before his occupation at AstraZeneca, he pursued a long academic career at Chalmers University of Technology and Harvard University. During his time at Harvard, Thomas collaborated with Nobel laureate Professor E.J. Corey, focusing on the development of AI tools for organic chemistry.